But U.S. Rep. Tom Davis of Virginia sent a letter to FDA's acting commissioner giving him two weeks to answer questions about how FDA tracks problems with drug safety. 
The Food and Drug Administration silenced one of its drug experts who raised safety concerns weeks before Merck Co. yanked the blockbuster drug Vioxx due to increased risks for heart attack and strokes. 
The announcement comes just two weeks after Merck pulled its painkiller from the market because a study showed that the risk of heart attacks doubled for patients who had taken Vioxx for 18 months or longer.
